dopamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics 947 51-61-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dopamine
  • oxytyramine
  • dopamin
  • dophamine
  • hydroxytyramin
  • dopamine hydrochloride
  • dopamine HCl
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
  • Molecular weight: 153.18
  • Formula: C8H11NO2
  • CLOGP: 0.17
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 3
  • TPSA: 66.48
  • ALOGS: -1.31
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 470 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.74 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 65.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.87 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 18.96 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 101.53 25.37 56 3979 56696 63428291
Renal ischaemia 73.89 25.37 15 4020 618 63484369
Cardiac arrest 69.68 25.37 53 3982 92492 63392495
Drug ineffective 65.51 25.37 178 3857 1044587 62440400
PCO2 increased 63.85 25.37 15 4020 1224 63483763
Hypotension 61.76 25.37 81 3954 272523 63212464
Blood bicarbonate decreased 59.90 25.37 17 4018 2924 63482063
Left ventricle outflow tract obstruction 59.12 25.37 11 4024 285 63484702
PO2 increased 57.92 25.37 13 4022 866 63484121
Diabetes insipidus 57.21 25.37 16 4019 2609 63482378
Cardiogenic shock 56.53 25.37 26 4009 17906 63467081
Blood pH decreased 52.89 25.37 15 4020 2572 63482415
Oxygen saturation abnormal 52.53 25.37 16 4019 3513 63481474
Status epilepticus 50.89 25.37 23 4012 15210 63469777
Shock 47.04 25.37 25 4010 23438 63461549
Renal impairment 46.28 25.37 41 3994 88314 63396673
Foetal death 44.52 25.37 19 4016 10961 63474026
Bradycardia 40.39 25.37 35 4000 73192 63411795
Electroencephalogram abnormal 39.52 25.37 13 4022 3659 63481328
Ventricular tachycardia 39.24 25.37 21 4014 19958 63465029
Enzyme induction 37.98 25.37 6 4029 56 63484931
Clonus 36.55 25.37 13 4022 4623 63480364
Cardiopulmonary failure 35.73 25.37 12 4023 3600 63481387
Blood magnesium decreased 35.02 25.37 17 4018 13181 63471806
Metabolic acidosis 34.28 25.37 26 4009 45043 63439944
Seizure 34.02 25.37 42 3993 132592 63352395
Renal injury 33.91 25.37 15 4020 9424 63475563
Pulmonary oedema 33.89 25.37 28 4007 54845 63430142
Left ventricular dysfunction 33.50 25.37 16 4019 11972 63473015
Electrocardiogram QRS complex prolonged 33.41 25.37 13 4022 5925 63479062
Disseminated intravascular coagulation 31.83 25.37 18 4017 19033 63465954
Blood pressure decreased 31.71 25.37 29 4006 64993 63419994
Renal failure 31.37 25.37 38 3997 117614 63367373
Cardiac assistance device user 31.25 25.37 5 4030 51 63484936
Newborn persistent pulmonary hypertension 29.99 25.37 6 4029 229 63484758
Platelet count decreased 28.53 25.37 36 3999 116086 63368901
Septic shock 27.32 25.37 27 4008 66602 63418385
Myocardial ischaemia 26.61 25.37 14 4021 12845 63472142
Systolic anterior motion of mitral valve 26.47 25.37 4 4031 27 63484960
Respiratory failure 25.69 25.37 32 4003 101826 63383161

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 68.50 21.90 156 3834 456595 34496346
Multiple organ dysfunction syndrome 58.92 21.90 57 3933 76509 34876432
Disseminated intravascular coagulation 49.76 21.90 31 3959 21785 34931156
Hypotension 43.76 21.90 85 3905 221564 34731377
Shock 39.72 21.90 28 3962 24151 34928790
Torsade de pointes 38.40 21.90 18 3972 7191 34945750
Blood urea increased 38.30 21.90 30 3960 30334 34922607
Ventricular fibrillation 34.08 21.90 25 3965 22929 34930012
Cardiac arrest 32.50 21.90 47 3943 96112 34856829
Acute kidney injury 31.66 21.90 91 3899 304897 34648044
Metabolic acidosis 30.72 21.90 31 3959 43649 34909292
Oliguria 24.55 21.90 14 3976 8366 34944575
Renal failure 24.38 21.90 49 3941 130508 34822433
Neutrophil count increased 23.93 21.90 18 3972 17128 34935813
Lymphocyte count decreased 23.56 21.90 20 3970 22602 34930339
Acidosis 23.56 21.90 15 3975 10930 34942011
Respiratory failure 23.01 21.90 43 3947 108529 34844412
Dry gangrene 22.77 21.90 6 3984 433 34952508
Cardiogenic shock 22.68 21.90 21 3969 26597 34926344

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 114.96 21.18 92 7193 120154 79616949
Drug ineffective 106.54 21.18 274 7011 1080639 78656464
Hypotension 89.82 21.18 151 7134 440166 79296937
Cardiac arrest 88.45 21.18 93 7192 172003 79565100
Shock 78.16 21.18 49 7236 43499 79693604
Disseminated intravascular coagulation 76.32 21.18 45 7240 35797 79701306
Cardiogenic shock 67.37 21.18 44 7241 41870 79695233
Renal ischaemia 59.39 21.18 15 7270 1147 79735956
Blood urea increased 59.03 21.18 43 7242 48747 79688356
PCO2 increased 57.08 21.18 16 7269 1824 79735279
Ventricular fibrillation 52.49 21.18 34 7251 31892 79705211
Left ventricle outflow tract obstruction 51.47 21.18 11 7274 402 79736701
Metabolic acidosis 50.37 21.18 49 7236 82480 79654623
Diabetes insipidus 47.80 21.18 18 7267 5219 79731884
Septic shock 47.02 21.18 57 7228 122744 79614359
Ventricular tachycardia 46.33 21.18 35 7250 41900 79695203
Renal impairment 45.99 21.18 64 7221 157719 79579384
Blood pH decreased 45.95 21.18 17 7268 4694 79732409
PO2 increased 45.60 21.18 13 7272 1575 79735528
Respiratory failure 44.90 21.18 68 7217 180843 79556260
Blood bicarbonate decreased 44.34 21.18 17 7268 5174 79731929
Foetal death 43.56 21.18 19 7266 8025 79729078
Acute kidney injury 42.97 21.18 124 7161 519280 79217823
Oxygen saturation abnormal 42.73 21.18 16 7269 4566 79732537
Bradycardia 41.02 21.18 56 7229 135501 79601602
Pulmonary oedema 38.82 21.18 44 7241 88210 79648893
Renal failure 38.26 21.18 67 7218 200901 79536202
Blood pressure decreased 37.79 21.18 46 7239 99420 79637683
Fatigue 34.87 21.18 21 7264 929706 78807397
Status epilepticus 34.73 21.18 24 7261 25017 79712086
Platelet count decreased 33.35 21.18 62 7223 194602 79542501
Torsade de pointes 32.80 21.18 21 7264 19291 79717812
Enzyme induction 31.79 21.18 6 7279 115 79736988
Arthralgia 31.31 21.18 7 7278 571796 79165307
Left ventricular dysfunction 30.30 21.18 20 7265 19341 79717762
Electroencephalogram abnormal 29.96 21.18 13 7272 5421 79731682
Acidosis 29.93 21.18 20 7265 19742 79717361
Neutrophil count increased 29.11 21.18 23 7262 29373 79707730
Cardiac failure 28.64 21.18 51 7234 154791 79582312
Blood magnesium decreased 28.15 21.18 18 7267 16494 79720609
Hepatic function abnormal 28.06 21.18 34 7251 73073 79664030
Sepsis 27.92 21.18 70 7215 269358 79467745
Hypernatraemia 27.78 21.18 17 7268 14434 79722669
Seizure 27.29 21.18 56 7229 188778 79548325
Clonus 27.09 21.18 13 7272 6827 79730276
Cardiac assistance device user 26.85 21.18 5 7280 89 79737014
Incision site pain 26.82 21.18 10 7275 2820 79734283
Drug ineffective for unapproved indication 26.80 21.18 28 7257 51210 79685893
Toxic epidermal necrolysis 26.30 21.18 26 7259 44555 79692548
Circulatory collapse 24.16 21.18 23 7262 37645 79699458
Electrocardiogram QRS complex prolonged 24.09 21.18 14 7271 10819 79726284
Systolic dysfunction 23.97 21.18 10 7275 3785 79733318
Lymphocyte count decreased 23.24 21.18 25 7260 47264 79689839
Myocardial ischaemia 23.21 21.18 19 7266 25500 79711603
Hepatic failure 22.73 21.18 28 7257 61184 79675919
Haemodynamic instability 22.57 21.18 16 7269 17366 79719737
Systolic anterior motion of mitral valve 22.45 21.18 4 7281 55 79737048
Intentional overdose 22.34 21.18 37 7248 105923 79631180
Urine output decreased 22.05 21.18 16 7269 18006 79719097
N-terminal prohormone brain natriuretic peptide 21.59 21.18 4 7281 69 79737034
Sinus bradycardia 21.31 21.18 18 7267 25229 79711874
Cardiopulmonary failure 21.24 21.18 11 7274 6790 79730313

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA04 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA CS M0003647 Catecholamines
FDA EPC N0000175570 Catecholamine
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:38147 cardiotonic drugs
CHEBI has role CHEBI:48560 dopaminergic agents
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Low cardiac output syndrome indication 44088000
Low blood pressure indication 45007003
Decompensated cardiac failure indication 195111005
Sinus bradycardia off-label use 49710005
Acute nephropathy off-label use 58574008
Tachyarrhythmia contraindication 6285003
Hypovolemia contraindication 28560003
Ventricular arrhythmia contraindication 44103008
Acidosis contraindication 51387008
Pheochromocytoma contraindication 302835009
Hypoxia contraindication 389086002
Occlusive Vascular Disease contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.96 acidic
pKa2 12.98 acidic
pKa3 10.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR AGONIST Ki 5 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 4.19 CHEMBL
D(1A) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
D(2) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter IC50 8.18 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 5.08 PDSP
D(3) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
D(1B) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.19 CHEMBL
D(4) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Trace amine-associated receptor 1 GPCR Ki 6.38 WOMBAT-PK
Melatonin receptor type 1A GPCR Ki 5.15 CHEMBL
Melatonin receptor type 1B GPCR Ki 5.04 CHEMBL
Lysine-specific demethylase 4E Enzyme IC50 5.52 CHEMBL
Dopamine beta-hydroxylase Enzyme Km 3 WOMBAT-PK
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.85 CHEMBL
Alpha-synuclein Transporter IC50 6.28 CHEMBL
D(2) dopamine receptor GPCR Ki 8.35 CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 6.70 CHEMBL
D(1A) dopamine receptor GPCR Ki 8.15 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.82 CHEMBL
D(2) dopamine receptor GPCR Ki 8.74 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 4.30 CHEMBL
D(3) dopamine receptor GPCR Ki 7.96 CHEMBL
D(4) dopamine receptor GPCR EC50 8.62 CHEMBL
Opioid receptor GPCR IC50 5.52 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.24 CHEMBL
Dopamine receptor GPCR IC50 8.43 CHEMBL
Dopamine receptor GPCR IC50 5.27 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 4.85 CHEMBL
Adenylate cyclase Enzyme EC50 5.46 CHEMBL
Adenosine A2b receptor GPCR Ki 6.01 CHEMBL
M18 aspartyl aminopeptidase Enzyme IC50 5.70 CHEMBL

External reference:

IDSource
4019733 VUID
N0000147825 NUI
D00633 KEGG_DRUG
62-31-7 SECONDARY_CAS_RN
4018656 VANDF
4019733 VANDF
C0013030 UMLSCUI
CHEBI:18243 CHEBI
LDP PDB_CHEM_ID
CHEMBL59 ChEMBL_ID
DB00988 DRUGBANK_ID
CHEMBL1557 ChEMBL_ID
D004298 MESH_DESCRIPTOR_UI
681 PUBCHEM_CID
2417 INN_ID
940 IUPHAR_LIGAND_ID
VTD58H1Z2X UNII
3628 RXNORM
3090 MMSL
4632 MMSL
6641 MMSL
d00216 MMSL
001787 NDDF
004721 NDDF
16257000 SNOMEDCT_US
412383006 SNOMEDCT_US
59187003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9252 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9252 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9253 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9253 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9254 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9254 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9255 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9255 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
MYOCARD-DX HUMAN PRESCRIPTION DRUG LABEL 2 0264-1840 INJECTION 80 mg INTRAVENOUS EXPORT ONLY 20 sections
MYOCARD-DX HUMAN PRESCRIPTION DRUG LABEL 2 0264-1840 INJECTION 80 mg INTRAVENOUS EXPORT ONLY 20 sections
MYOCARD-DX HUMAN PRESCRIPTION DRUG LABEL 2 0264-1880 INJECTION 800 mg INTRAVENOUS EXPORT ONLY 20 sections
MYOCARD-DX HUMAN PRESCRIPTION DRUG LABEL 2 0264-1880 INJECTION 800 mg INTRAVENOUS EXPORT ONLY 20 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1005 INJECTION, SOLUTION 80 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1005 INJECTION, SOLUTION 80 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1007 INJECTION, SOLUTION 160 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1007 INJECTION, SOLUTION 160 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1009 INJECTION, SOLUTION 320 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1009 INJECTION, SOLUTION 320 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9981 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9981 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9982 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9982 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-5820 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 17 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-7809 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 25 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-7810 INJECTION, SOLUTION 3.20 mg INTRAVENOUS NDA 25 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-9104 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 17 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1220 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1220 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1291 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1291 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections